Aronson v. Kinsella

58 Cal. App. 4th 254, 68 Cal. Rptr. 2d 254, 97 Daily Journal DAR 12799, 97 Cal. Daily Op. Serv. 7953, 1997 Cal. App. LEXIS 817
CourtCalifornia Court of Appeal
DecidedOctober 10, 1997
DocketD022306
StatusPublished
Cited by45 cases

This text of 58 Cal. App. 4th 254 (Aronson v. Kinsella) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aronson v. Kinsella, 58 Cal. App. 4th 254, 68 Cal. Rptr. 2d 254, 97 Daily Journal DAR 12799, 97 Cal. Daily Op. Serv. 7953, 1997 Cal. App. LEXIS 817 (Cal. Ct. App. 1997).

Opinion

Opinion

KREMER, P. J.

Gary D. Aronson appeals a summary judgment on his defamation action against Kevin J. Kinsella. Aronson contends the court misapplied the standard for determining whether prelitigation statements are covered by the litigation privilege (Civ. Code, 1 § 47, subd. (b)) and improperly ruled Kinsella had not waived the attorney-client and work product privileges. Kinsella also appeals, contending summary judgment should have been granted on the ground Aronson could prove no damages and therefore was libel-proof. We affirm.

Facts

In 1983, Kinsella formed the venture capital firm of Avalon Ventures (hereafter Avalon). Avalon was involved in the founding of Vertex Pharmaceuticals (hereafter Vertex) (in 1989) and GenPharm International (in 1988).

In May 1987, Avalon entered into a “letter agreement” with Aronson where Avalon agreed to assign one-third of any founders’ stock or warrants which Avalon received in new start-up companies and to reimburse Aron-son’s expenses for “any new start-up company that [Aronson] might bring to [Avalon] which [met] [Avalon’s] investment criteria,” providing Aronson originated the idea for the company and did “sufficient work to determine the potential upside of the company.” 2 While with Avalon, Aronson worked on the Vertex project. He also worked on the Chimera project. Chimera Biotech (hereafter Chimera) was a company which later became a part of GenPharm International. By March 1990, Aronson was no longer working with Avalon.

Kinsella and Aronson disputed how much Aronson contributed to the formation of Vertex and GenPharm International.

*258 According to Kinsella, in the biotechnology venture capital field a person who has helped to “establish,” to “found,” or to “finance” a start-up company means the individual was a “prime mover" in the formation of the company and was involved in recruiting leading scientists with promising technologies, preeminent advisers and experienced business managers; developing business plans; and providing capital and seeking additional investors from the venture capital community. Kinsella stated Aronson did not help to found or finance Vertex because Aronson “performed none of the primary tasks typically considered to be involved in founding a company,” i.e., recruiting scientific advisors, management personnel or employees, facilitating the acquisition of any technology, bringing in financing, or making any substantial or important contributions to Vertex’s business plan. According to Kinsella, he rather than Aronson performed these tasks.

According to Kinsella, Aronson never worked on the formation or financing of GenPharm International but worked directly for Kinsella only on Chimera, a company which was later acquired by GenPharm International. When Chimera was acquired by GenPharm International, Aronson’s consulting work on this project ended. Aronson’s final compensation for work performed on Chimera was paid by GenPharm International as successor to Chimera’s obligation.

Aronson presented evidence, including his declaration, tending to support a conclusion he was involved in helping to found or finance Vertex. Among other things, there was a letter of reference for Aronson by Lawrence Bock who became a partner in Avalon in 1989. This letter, written in March 1990 states: “In the case of both GenPharm and Vertex, Mr. Aronson made major contributions and received an equity interest as part of his compensation.” 3

Aronson stated in a declaration that he helped to establish and/or finance not only Vertex but also “GenPharm.” In his deposition, he stated he had worked on Chimera which merged with GenPharm to create GenPharm International and since he “performed considerable work” on one of the two companies which formed GenPharm International, he concluded he “performed work on the resultant company.”

A dispute arose between Aronson and Kinsella about the amount of compensation Aronson was entitled to for working on the Vertex project. Avalon filed a declaratory relief action in February 1991 against Aronson and Aronson’s consulting company. Aronson cross-complained against Avalon and Kinsella for breach of the May 1987 letter agreement. The jury *259 awarded Aronson over $1.6 million (the value of one-third of Avalon’s stock and warrants in Vertex at that time) on Aronson’s breach of contract claim. The trial judge decided the quantum meruit value of Aronson’s services to Avalon was $300,000.

In 1992, Aronson was president of DepoTech Corporation (hereafter DepoTech), a biotechnology company. DepoTech circulated a business plan to raise investment capital which stated, inter alia, that Aronson had assisted in “the founding of seven companies and the financing of two others. These companies include: . . . GenPharm International, Vertex Pharmaceuticals . . . .” The business plan also included Aronson’s resume which stated he “helped to establish and/or finance” the companies listed in the business plan.

Kinsella received a portion of this business plan from another venture capitalist in July 1992. Kinsella objected to Aronson taking credit for the founding or financing of GenPharm International and Vertex because Kinsella believed he had founded or financed those companies. Kinsella retained a law clerk to do legal research on DepoTech’s claims in his business plan and consulted with three different attorneys about whether he had a basis for suing Aronson for making false claims. The attorneys advised him he had a valid claim. Kinsella stated he intended to bring whatever legal action would be necessary to stop DepoTech (and Aronson) from continuing “this false advertising and unfair business competition.” One of Kinsella’s attorneys, Michael O’Donnell, testified in his deposition that Kinsella stated he would pursue a lawsuit if the matter were not resolved.

On October 26, 1992, Kinsella’s attorney, Mauricio Flores, wrote the following letter to the chairman of DepoTech:

“We represent Mr. Kevin J. Kinsella. It has come to our attention that you are listed as the Chairman and Chief Executive of DepoTech Corporation of San Diego, California, on a business plan dated January 1992, which is currently being circulated among potential venture capital investors and perhaps others. This business plan includes several pages constituting the ‘Firm Resume’ of Gary D. Aronson Consulting. We believe that several statements and claims by Mr. Aronson, listed as the President of DepoTech Corporation, are false and misleading.
“Specifically, the statements that ‘GDAC has helped establish and/or finance Vertex Pharmaceuticals’ and ‘GenPharm International’ are untrue and misleading statements contained in the business plan. Mr. Aronson played no role in either the founding or the financing of Vertex or GenPharm. These statements reflect adversely on Mr. Kinsella, who did in fact play a major role in both.
*260 “Such statements violate California Business and Professions Code Sections 17500 et seq. relating to deceptive, untrue or misleading advertising constituting unfair competition.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Osborne v. Pleasanton Automotive Co., LP
California Court of Appeal, 2024
Medallion Film LLC v. Loeb & Loeb LLP
California Court of Appeal, 2024
ZL Technologies v. Srinivasan CA6
California Court of Appeal, 2023
Lankster v. Compton Unified School Dist. CA2/3
California Court of Appeal, 2021
Dutton v. Ouriel CA2/2
California Court of Appeal, 2021
People v. Toledano
California Court of Appeal, 2019
People v. Toledano
249 Cal. Rptr. 3d 100 (California Court of Appeals, 5th District, 2019)
Dickinson v. Cosby
California Court of Appeal, 2017
Dickinson v. Cosby
225 Cal. Rptr. 3d 430 (California Court of Appeals, 5th District, 2017)
DeMichael-Lucas v. Nelson CA4/2
California Court of Appeal, 2016
Sotelo v. Fernandez CA2/8
California Court of Appeal, 2015
Weksler v. Weksler CA2/4
California Court of Appeal, 2015
Ingrid & Isabel, LLC v. Baby Be Mine, LLC
70 F. Supp. 3d 1105 (N.D. California, 2014)
Hanover Insurance v. Fremont Bank
68 F. Supp. 3d 1085 (N.D. California, 2014)
Praetorian Ins. Co. v. The Dunnon Law Firm CA5
California Court of Appeal, 2014
Kirsch v. Redwood Recovery Services CA2/2
California Court of Appeal, 2014
Zhang v. Cheng CA2/1
California Court of Appeal, 2013
Lopez v. Broukhim CA2/8
California Court of Appeal, 2013

Cite This Page — Counsel Stack

Bluebook (online)
58 Cal. App. 4th 254, 68 Cal. Rptr. 2d 254, 97 Daily Journal DAR 12799, 97 Cal. Daily Op. Serv. 7953, 1997 Cal. App. LEXIS 817, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aronson-v-kinsella-calctapp-1997.